Cite
HARVARD Citation
Kalluri, H. et al. (2023). Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Annals of neurology. 93 (2), pp. 285-296. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kalluri, H. et al. (2023). Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Annals of neurology. 93 (2), pp. 285-296. [Online].